<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is the third most common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Anti-epidermal growth factor receptor (EGFR)-targeted therapy shows clinical evidence in this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> and improves outcome </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene phosphatase and tensin homologue (PTEN) is considered a potential predictor of nonresponse to anti-EGFR agents </plain></SENT>
<SENT sid="3" pm="."><plain>The purpose of this study was to assess whether associations between PTEN alterations (PTEN gene deletion or PTEN gene disruption) and clinical outcome could be caused by a prognostic (and not predictive) effect of PTEN inactivation </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, we analyzed 404 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> not previously treated with anti-EGFR drugs in a tissue microarray format </plain></SENT>
<SENT sid="5" pm="."><plain>PTEN deletion and PTEN gene rearrangements were analyzed by fluorescence in situ hybridization </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0001425'>Heterogeneity</z:hpo> analysis of <z:hpo ids='HP_0000001'>all</z:hpo> available large tissue sections was performed in 6 cases with genomic PTEN alteration </plain></SENT>
<SENT sid="7" pm="."><plain>Twenty-seven (8.8%) of 307 analyzable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> spots showed genomic PTEN alterations including 24 hemizygous and 1 homozygous deletion as well as 2 PTEN gene disruptions </plain></SENT>
<SENT sid="8" pm="."><plain>Genomic PTEN alterations were associated with reduced patient survival in <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> in univariate and multivariate analyses (P = .012; hazard ratio, 2.675; 95% confidence interval, 1.242-5.759) but not in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Large-section evaluation revealed a homogeneous distribution pattern in <z:hpo ids='HP_0000001'>all</z:hpo> 4 analyzed cases with PTEN deletion and in both cases with a PTEN gene disruption </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, genomic PTEN gene alterations caused by deletion or gene disruption characterize a fraction of <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancers</z:e> with particularly poor outcome </plain></SENT>
</text></document>